TotalClarity Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • TotalClarity's estimated annual revenue is currently $620k per year.(i)
  • TotalClarity's estimated revenue per employee is $155,000

Employee Data

  • TotalClarity has 4 Employees.(i)
  • TotalClarity grew their employee count by -20% last year.

TotalClarity's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is TotalClarity?

TotalClarity is a next generation bio-pharmaceutical company. We are a global platform, developing innovative pharmaceutical products by acquiring novel IP and nurturing them through the entire life-cycle – from idea to successful commercialization. TotalClarity is passionate about developing and enhancing existing drugs and creation of novel molecular entities. We have a pipeline of pre-clinical drug candidates in the areas of oncology and pulmonary medicine which hold promise of being life changing therapies for patients. Inhalation therapeutic treatments, for invasive fungal infections (IFI), is a special area of interest for us. In addition to the intellectual assets, we intend to have our own specialized manufacturing facility which will be a leader in particle engineering for inhalation products. Our oncology pipeline aims to address many safety issues associated with clinically known target therapies. The resulting drug candidates are novel kinase inhibitors with enhanced safety, efficacy, and tolerability profile.

keywords:N/A

N/A

Total Funding

4

Number of Employees

$620k

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A40%N/A
#2
$0.3M4-20%N/A
#3
$0.5M40%N/A
#4
N/A4-86%N/A
#5
$0.3M4-67%N/A